Susceptibility of p27kip1 knockout mice to urinary bladder carcinogenesis induced by N-butyl-N-(4-hydroxybutyl)nitrosamine may not simply be due to enhanced proliferation

International Journal of Cancer

Volumn 122, Issue 6, 2008, Pages 1222-1228

  Hikosaka, Atsuya ^a   Ogawa, Kumiko ^a   Sugiura, Satoshi ^a   Asamoto, Makoto ^a   Takeshita, Fumitaka ^a   Sato, Shin Ya ^a   Nakanishi, Makoto ^a   Kohri, Kenjiro ^a   Shirai, Tomoyuki ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

BBN; Knockout mice; p27; Urinary bladder

Indexed keywords

BROXURIDINE; CARCINOGEN; CYCLIN DEPENDENT KINASE INHIBITOR 1B; DRINKING WATER; N BUTYL N (4 HYDROXYBUTYL)NITROSAMINE;

ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER; BLADDER CARCINOGENESIS; CANCER SUSCEPTIBILITY; CELL CYCLE; CONTROLLED STUDY; FEMALE; GENETIC VARIABILITY; GENOTYPE; IMMUNOHISTOCHEMISTRY; KIDNEY PELVIS; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SINGLE STRAND CONFORMATION POLYMORPHISM; STATISTICAL SIGNIFICANCE; UROTHELIUM; WILD TYPE;

ANIMALS; BASE SEQUENCE; BODY WEIGHT; BUTYLHYDROXYBUTYLNITROSAMINE; CARCINOGENS; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DNA PRIMERS; FEMALE; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; ORGAN SIZE; URINARY BLADDER NEOPLASMS;

EID: 39649093873     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23249     Document Type: Article

References (40)

1. Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994;78:59-66.
2. Toyoshima H, Hunter T. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 1994;78:67-74.
3. Kato JY, Matsuoka M, Polyak K, Massague J, Sherr CJ. Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27Kip1) of cyclin-dependent kinase 4 activation. Cell 1994;79:487-96.
4. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999;13:1501-12.
5. Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, Yew PR, Draetta GF, Rolfe M. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995;269:682-5.
6. Viglietto G, Motti ML, Bruni P, Melillo RM, D'Alessio A, Califano D, Vinci F, Chiappetta G, Tsichlis P, Bellacosa A, Fusco A, Santoro M. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. Nat Med 2002;8:1136-44.
7. Shin I, Yakes FM, Rojo F, Shin NY, Bakin AV, Baselga J, Arteaga CL. PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization. Nat Med 2002;8:1145-52.
8. Liang J, Zubovitz J, Petrocelli T, Kotchetkov R, Connor MK, Han K, Lee JH, Ciarallo S, Catzavelos C, Beniston R, Franssen E, Slingerland JM. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat Med 2002;8:1153-60.
9. Kip1 gene to 12p13 and its analysis in leukemias. Cancer Res 1995;55:1206-10.
10. Kip1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors. Cancer Res 1995;55:1211-4.
11. Spirin KS, Simpson JF, Takeuchi S, Kawamata N, Miller CW, Koeffler HP. p27/Kip1 mutation found in breast cancer. Cancer Res 1996;56:2400-4.
12. Kip1 protein: prognostic implications in primary breast cancer. Nature Med 1997;3:227-30.
13. Kip1 and cycltn E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 1997;3:222-5.
14. 1a,b) invasive breast carcinomas. Cancer Res 1997;57:1259-63.
15. Mori M, Mimori K, Shiraishi T, Tanaka S, Ueo H, Sugimachi K, Akiyoshi T. p27 expression and gastric carcinoma. Nat Med 1997;3:593.
16. Loda M, Cukor B, Tam SW, Lavin P, Fiorentino M, Draetta GF, Jessup JM, Pagano M. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nature Med 1997;3:231-4.
17. Newcomb EW, Sosnow M, Demopoulos RI, Zeleniuch-Jacquotte A, Sorich J, Speyer JL. Expression of the cell cycle inhibitor p27KIP1 is a new prognostic marker associated with survival in epithelial ovarian tumors. Am J Pathol 1999;154:119-25.
18. Sui L, Tokuda M, Ohno M, Hatase O, Hando T. The concurrent expression of p27(kip1) and cyclin D1 in epithelial ovarian tumors. Gynecol Oncol 1999;73:202-9.
19. Masciullo V, Sgambato A, Pacilio C, Pucci B, Ferrandina G, Palazzo J, Carbone A, Cittadini A, Mancuso S, Scambia G, Giordano A. Frequent loss of expression of the cyclin-dependent kinase inhibitor p27 in epithelial ovarian cancer. Cancer Res 1999;59:3790-4.
20. Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res 1998;58:542-8.
21. Cote RJ, Shi Y, Groshen S, Feng AC, Cordon-Cardo C, Skinner D, Lieskovosky G. Association of p27Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma. J Natl Cancer Inst 1998;90:916-20.
22. Kip1 expression correlates with tumor grade and with reduced disease-free survival in primary superficial bladder cancers. Cancer Res 1999;59:3245-50.
23. Korkolopoulou P, Christodoulou P, Konstantinidou AE, Thomas-Tsagli E, Kapralos P, Davaris P. Cell cycle regulators in bladder cancer: a multivariate survival study with emphasis on p27Kip1. Hum Pathol 2000;31:751-60.
24. Kip1 and cyclin E protein levels is associated with progression from superficial into invasive bladder cancer. Br J Cancer 2001;84:1242-51.
25. Kip1 is associated with malignant transformation of the rat urinary bladder epithelium. Carcinogenesis 2000;21:117-21.
26. Kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 1996;85:707-20.
27. Cohen SM. Comparative pathology of proliferative lesions of the urinary bladder. Toxicol Pathol 2002;30:663-71.
28. Ogawa K, Uzvolgyi É, St. John MK, de Oliveira ML, Arnold L, Cohen SM. Frequent p53 mutations and occasional loss of chromosome 4 in invasive bladder carcinoma induced by N-butyl-N-(4-hydroxybutyl) nitrosamine in B6D2F1 mice. Mol Carcinog 1998;21:70-9.
29. Fukushima S, Imaida K, Sakata T, Okamura T, Shibata M-A, Ito N. Promoting effects of sodium L-ascorbate on two-stage urinary bladder carcinogenesis in rats. Cancer Res 1983;43:4454-7.
30. Kip1 is haplo-insufficient for tumor suppression. Nature 1998;396:177-80.
31. Doganay L, Altaner S, Bilgi S, Kaya E, Ekuklu G, Kutlu K. Expression of the cyclin-dependent kinase inhibitor p27 in transitional cell bladder cancers: is it a good predictor for tumor behavior? Int Urol Nephrol 2003;35:181-8.
32. Philipp J, Vo K, Gurley KE, Seidel K, Kemp CJ. Tumor suppression by p27Kip1 and p21Cip1 during chemically induced skin carcinogenesis. Oncogene 1999;18:4689-98.
33. Jackson RJ, Adnane J, Coppola D, Cantor A, Sebti SM, Pledger WJ. Loss of the cell cycle inhibitors p21(Cip1) and p27(Kip1) enhances tumorigenesis in knockout mouse models. Oncogene 2002;21:8486-97.
34. Di Cristofano A, De Acetis M, Koff A, Cordon-Cardo C, Pandolfi PP. Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nat Genet 2001;27:222-41.
35. Shaffer DR, Viale A, Ishiwata R, Leversha M, Olgac S, Manova K, Satagopan J, Scher H, Koff A. Evidence for a p27 tumor suppressive function independent of its role regulating cell proliferation in the prostate. Proc Natl Acad Scei USA 2005;102:210-5.
36. Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc Natl Acad Scei USA 2006;103:15558-63.
37. Bryant P, Zheng Q, Pumiglia K. Focal adhesion kinase controls cellular levels of p27/Kip1 and p21/Cip1 through Skp2-dependent and -independent mechanisms. Mol Cell Biol 2006;26:4201-13.
38. Ogino S, Kawasaki T, Kirkner GJ, Yamaji T, Loda M, Fuchs CS. Loss of nuclear p27 (CDKN1B/KIP1) in colorectal cancer is correlated with microsatellite instability and CIMP. Mod Pathol 2007;20:15-22.
39. Min YH, Cheong JW, Kim JY, Eom JI, Lee ST, Hahn JS, Ko YW, Lee MH. Cytoplasmic mislocalization of p27Kip1 protein is associated with constitutive phosphorylation of Akt or protein kinase B and poor prognosis in acute myelogenous leukemia. Cancer Res 2004;64:5225-31.
40. Kip1 that causes stem cell expansion and a multiple tumor phenotype. Genes Dev 2007;21:1731-46.